Native/citrullinated LL37-specific T-cells help autoantibody production in Systemic Lupus Erythematosus.

Anti-Citrullinated Protein Antibodies / immunology Antibodies, Antinuclear / immunology Antibody Formation / immunology Antimicrobial Cationic Peptides / immunology Autoantibodies / immunology DNA / immunology Dendritic Cells / immunology Female Humans Lupus Erythematosus, Systemic / etiology Male Psoriasis / etiology T-Lymphocytes / immunology Th17 Cells / immunology Cathelicidins

Journal

Scientific reports
ISSN: 2045-2322
Titre abrégé: Sci Rep
Pays: England
ID NLM: 101563288

Informations de publication

Date de publication:
03 04 2020
Historique:
received: 09 01 2020
accepted: 12 03 2020
entrez: 5 4 2020
pubmed: 5 4 2020
medline: 1 12 2020
Statut: epublish

Résumé

LL37 exerts a dual pathogenic role in psoriasis. Bound to self-DNA/RNA, LL37 licenses autoreactivity by stimulating plasmacytoid dendritic cells-(pDCs)-Type I interferon (IFN-I) and acts as autoantigen for pathogenic Th17-cells. In systemic lupus erythematosus (SLE), LL37 also triggers IFN-I in pDCs and is target of pathogenic autoantibodies. However, whether LL37 activates T-cells in SLE and how the latter differ from psoriasis LL37-specific T-cells is unknown. Here we found that 45% SLE patients had circulating T-cells strongly responding to LL37, which correlate with anti-LL37 antibodies/disease activity. In contrast to psoriatic Th17-cells, these LL37-specific SLE T-cells displayed a T-follicular helper-(T

Identifiants

DOI: 10.1038/s41598-020-62480-3 PMID: 32245990 PMC: PMC7125190
pubmed: 32245990
doi: 10.1038/s41598-020-62480-3
pii: 10.1038/s41598-020-62480-3
pmc: PMC7125190
doi:

Substances chimiques

Anti-Citrullinated Protein Antibodies 0
Antibodies, Antinuclear 0
Antimicrobial Cationic Peptides 0
Autoantibodies 0
DNA 9007-49-2
Cathelicidins 0

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

5851

Références

Tsokos, G. C. Systemic lupus erythematosus. N. Engl. J. Med. 365, 2110–2121 (2011).
pubmed: 22129255 doi: 10.1056/NEJMra1100359
Tan, E. M. Autoantibodies, autoimmune disease, and the birth of immune diagnostics. J. Clin. Invest. 122, 3835–3836 (2012).
pubmed: 23154275 pmcid: 3484082 doi: 10.1172/JCI66510
Thoeger, Z., Sharabi, A. & Mozes, E. Novel approaches to the development of targeted therapeutic agents for systemic lupus erythematosus. J. Autoimmun. 54, 60–71 (2014).
doi: 10.1016/j.jaut.2014.06.002
Fumeaux, D., de Seigneux, S., Chizzolini, C. & Martin, P. Y. Renal disease in ANCA-associated vasculitis. Rev. Med. Suisse. 10, 493–497 (2014).
pubmed: 24665659
Pieterse, E. & van der Vlag, J. Breaking immunological tolerance in systemic lupus erythematosus. Front. Immunol. 5, 164–171 (2014).
pubmed: 24782867 pmcid: 3988363 doi: 10.3389/fimmu.2014.00164
Lood, C. et al. Neutrophil extracellular traps enriched in oxidized mitochondrial DNA are interferogenic and contribute to lupus-like disease. Nat. Medicine. 22, 146–153 (2017).
doi: 10.1038/nm.4027
Caielli, S. et al. Oxidized mitochondrial nucleoids released by neutrophils drive type I interferon production in human lupus. J. Exp. Med. 213, 697–713 (2016).
pubmed: 27091841 pmcid: 4854735 doi: 10.1084/jem.20151876
Yurkovich, M., Vostretsova, K., Chen, W. & Aviña-Zubieta, J. A. Overall and cause-specific mortality in patients with systemic lupus erythematosus: a meta-analysis of observational studies. Arthritis Care Res (Hoboken). 66, 608–616 (2014).
pubmed: 24106157 doi: 10.1002/acr.22173
Lande, R. et al. Neutrophils activate plasmacytoid dendritic cells by releasing self-DNA-peptide complexes in systemic lupus erythematosus. Sci. Transl. Med. 3, 73ra19–38 (2011).
pubmed: 21389263 pmcid: 3399524 doi: 10.1126/scitranslmed.3001180
Lande, R. et al. Plasmacytoid dendritic cells sense self-DNA coupled with antimicrobial peptide. Nature. 449, 564–569 (2007).
pubmed: 17873860 doi: 10.1038/nature06116
Ganguly, D. et al. Self-RNA-antimicrobial peptide complexes activate human dendritic cells though TLR7 and TLR8. J. Exp. Med. 206, 1983–1994 (2009).
pubmed: 19703986 pmcid: 2737167 doi: 10.1084/jem.20090480
Chamilos, G. et al. Cytosolic sensing of extracellular self-DNA transported into monocytes by the antimicrobial peptide LL37. Blood. 120, 3699–3707 (2012).
pubmed: 22927244 pmcid: 3488884 doi: 10.1182/blood-2012-01-401364
Gestermann, N. et al. Netting neutrophils activate autoreactive B cells in Lupus. J. Immunol. 200, 3364–3371 (2018).
pubmed: 29632142 doi: 10.4049/jimmunol.1700778
Kreuter, A. et al. Expression of antimicrobial peptides in different subtypes of cutaneous lupus erythematosus. J. Am. Acad. Dermatol. 65, 125–133 (2011).
pubmed: 21353331 doi: 10.1016/j.jaad.2010.12.012
Sun, C. L., Zhang, F. Z., Li, P. & Bi, L. Q. LL-37 expression in the skin in systemic lupus erythematosus. Lupus. 20, 904–911 (2011).
pubmed: 21562016 doi: 10.1177/0961203311398515
Almaani, S., Meara, A. & Rovin, B. H. Update on Lupus Nephritis. CJASN. 12, 825–835 (2017).
pubmed: 27821390 doi: 10.2215/CJN.05780616
Lande, R. et al. The antimicrobial peptide LL37 is a T-cell autoantigen in psoriasis. Nat. Commun. 5, 5621–5635 (2014).
pubmed: 25470744 doi: 10.1038/ncomms6621
Cannons, J. L., Lu, K. T. & Schwartzberg, P. L. T follicular helper cell diversity and plasticity. Trends Immunol. 34, 200–207 (2013).
pubmed: 23395212 pmcid: 3646926 doi: 10.1016/j.it.2013.01.001
Park, J. J. et al. Insights into the role of follicular helper T cells in autoimmunity. Immune Netw. 14, 21–29 (2014).
pubmed: 24605077 pmcid: 3942504 doi: 10.4110/in.2014.14.1.21
Kilsgård, O. et al. Peptidylarginine deiminases present in the airways during tobacco smoking and inflammation can citrullinate the host defense peptide LL-37, resulting in altered activities. Am. J. Respir. Cell Mol. Biol. 46, 240–248 (2012).
pubmed: 21960546 doi: 10.1165/rcmb.2010-0500OC
Dwivedi, N. & Radic, M. Citrullination of autoantigens implicates NETosis in the induction of autoimmunity. Ann. Rheum. Dis. 73, 483–491 (2014).
pubmed: 24291655 doi: 10.1136/annrheumdis-2013-203844
Zhou, Y. et al. Spontaneous secretion of the citrullination enzyme PAD2 and cell surface exposure of PAD4 by neutrophils. Front Immunol. 8, 1200–1215 (2017).
pubmed: 28993780 pmcid: 5622307 doi: 10.3389/fimmu.2017.01200
Vejlstrup, A., Møller, A. M., Nielsen, C. H. & Damgaard, D. Release of active peptidylarginine deiminase into the circulation during acute inflammation induced by coronary artery bypass surgery. J. Inflamm. Res. 12, 137–144 (2019).
pubmed: 31213874 pmcid: 6549760 doi: 10.2147/JIR.S198611
Airò, P. et al. Upregulation of myxovirus-resistance protein A: a possible marker of type I interferon induction in systemic sclerosis. J. Rheumatol. 35, 2192–2200 (2008).
pubmed: 18843779 doi: 10.3899/jrheum.080418
Romero, V. et al. Immune-mediated pore-forming pathways induce cellular hypercitrullination and generate citrullinated autoantigens in rheumatoid arthritis. Sci. Transl. Med. 30, 209ra150 (2013).
Konig, M. F. & Andrade, F. A. Critical reappraisal of neutrophil extracellular traps and NETosis mimics based on differential requirements for protein citrullination. Front. Immunol. 7, 461–478 (2016).
pubmed: 27867381 pmcid: 5095114
Kienhöfer, D. et al. No evidence of pathogenic involvement of cathelicidins in patient cohorts and mouse models of lupus and arthritis. PLoS One. 9, e115474 (2014).
pubmed: 25535966 pmcid: 4275226 doi: 10.1371/journal.pone.0115474
Kuhn, A. & Landmann, A. The classification and diagnosis of cutaneous lupus erythematosus. J. Autoimmun. 48-49, 14–19 (2014).
pubmed: 24486120 doi: 10.1016/j.jaut.2014.01.021
Harder, J. & Schröder, J. M. Psoriatic scales: a promising source for the isolation of human skin-derived antimicrobial proteins. J. Leukoc. Biol. 77, 476–486 (2005).
pubmed: 15629886 doi: 10.1189/jlb.0704409
Kim, H. J. et al. LL-37 suppresses sodium nitroprusside-induced apoptosis of systemic sclerosis dermal fibroblasts. Exp. Dermatol. 20, 843–845 (2011).
pubmed: 21732986 doi: 10.1111/j.1600-0625.2011.01327.x
Hoffmann, M. H. et al. Cathelicidins LL-37 and rCRAMP are associated with pathogenic events of arthritis in humans and rats. Ann. Rheum. Dis. 72, 1239–1248 (2013).
pubmed: 23172753 doi: 10.1136/annrheumdis-2012-202218
Takahashi, T. et al. A potential contribution of antimicrobial peptide LL-37 to tissue fibrosis and vasculopathy in systemic sclerosis. Br. J. Dermatol. 175, 1195–1203 (2016).
pubmed: 27105895 doi: 10.1111/bjd.14699
Schauber, J. et al. Heterogeneous expression of human cathelicidin hCAP18/LL-37 in inflammatory bowel diseases. Eur. J. Gastroenterol. Hepatol. 18, 615–621 (2006).
pubmed: 16702850 doi: 10.1097/00042737-200606000-00007
Zhang, X. et al. Circulating CXCR5+CD4+helper T cells in systemic lupus erythematosus patients share phenotypic properties with germinal center follicular helper T cells and promote antibody production. Lupus. 24, 909–917 (2015).
pubmed: 25654980 doi: 10.1177/0961203314567750
Frasca, L. et al. Anti-LL37 antibodies are present in Psoriatic. Arthritis (PsA) patients: new biomarkers in PsA. Front. Immunol. 9, 1936–1952 (2018).
pubmed: 30279686
Quarona, V. et al. CD38 and CD157: a long journey from activation markers to multifunctional molecules. Cytometry B Clin. Cytom. 84, 207–217 (2013).
pubmed: 23576305 doi: 10.1002/cyto.b.21092
Gao, W., Wu, Y., Tian, Y. & Ni, B. Yin-Yang regulation of RORγt Protein Complex in Th17 differentiation. Int. Rev. Immunol. 34, 295–304 (2015).
pubmed: 25340306 doi: 10.3109/08830185.2014.969423
Hakkim, A. et al. Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc.Natl. Acad. Sci.USA 107, 9813–9818 (2010).
pubmed: 20439745 doi: 10.1073/pnas.0909927107
Thieblemont, N., Wright, H. L., Edwards, S. W. & Witko-Sarsat, V. Human neutrophils in auto-immunity. Semin. Immunol. 28, 159–173 (2016).
pubmed: 27036091 doi: 10.1016/j.smim.2016.03.004 pmcid: 27036091
Boeltz, S. et al. NET or not to NET: current opinions and state of the science regarding the formation of neutrophil extracellular traps. Cell Death Differ. 26, 395–408 (2019).
pubmed: 30622307 pmcid: 6370810 doi: 10.1038/s41418-018-0261-x
Singel, K. L. & Segal, B. H. NOX2-dependent regulation of inflammation. Clin. Sci. (Lond). 130, 479–490 (2016).
pubmed: 26888560 pmcid: 5513728 doi: 10.1042/CS20150660
Campbell, A. M., Kashgarian, M. & Shlomchik, M. J. NADPH oxidase inhibits the pathogenesis of systemic lupus erythematosus. Sci. Transl. Med. 4, 157ra141 (2012).
pubmed: 23100627 pmcid: 3704198 doi: 10.1126/scitranslmed.3004801
Kienhöfer, D. et al. Experimental lupus is aggravated in mouse strains with impaired induction of neutrophil extracellular traps. JCI Insight. 2, 92920 (2017).
pubmed: 28515366 doi: 10.1172/jci.insight.92920
Mistry, P. & Kaplan, M. J. Cell death in the pathogenesis of systemic lupus erythematosus and lupus nephritis. Clin.Immunol. 185, 159–173 (2017).
doi: 10.1016/j.clim.2016.08.010
Kraaij, T. et al. A novel method for high-throughput detection and quantification of neutrophil extracellular traps reveals ROS-independent NET release with immune complexes. Autoimm. Rev. 15, 577–584 (2016).
doi: 10.1016/j.autrev.2016.02.018
Kenny, E. F. et al. Diverse stimuli engage different neutrophil extracellular trap pathways. Elife. 6, e24437 (2017).
pubmed: 28574339 pmcid: 5496738 doi: 10.7554/eLife.24437
Pieterse, E. et al. Cleaved N-terminal histone tails distinguish between NADPH oxidase (NOX)-dependent and NOX-independent pathways of neutrophil extracellular trap formation. Ann Rheum. Dis. 77, 1790–1798 (2018).
pubmed: 30120096 doi: 10.1136/annrheumdis-2018-213223
Ziskind, M. & Koffler, D. Cutaneous localization of the membrane attack complex in discoid and systemic lupus erythematosus. N. Engl. J. Med. 306, 264–270 (1982).
pubmed: 7054697 doi: 10.1056/NEJM198202043060503
Botto, M. et al. Complement in human diseases: Lessons from complement deficiencies. Mol. Immunol. 46, 2774–2783 (2009).
pubmed: 19481265 doi: 10.1016/j.molimm.2009.04.029
Wang, S., Wu, M., Chiriboga, L., Zeck, B. & Belmont, H. B. Membrane attack complex (mac) deposition in lupus nephritis is associated with hypertension and poor clinical response to treatment. Semin. Arthritis Rheum. 48, 256–262 (2018).
pubmed: 29395256 doi: 10.1016/j.semarthrit.2018.01.004
Bollain-y-Goytia, J. J. et al. Widespread expression of inducible NOS and citrulline in lupus nephritis tissues. Inflamm. Res. 58, 61–66 (2009).
pubmed: 19184355 doi: 10.1007/s00011-009-7215-1
Chitrabamrung, S., Rubin, R. L. & Tan, E. M. Serum deoxyribonuclease I and clinical activity in systemic lupus erythematosus. Rheumatol. Int. 1, 55–60 (1981).
pubmed: 6287560 doi: 10.1007/BF00541153
Borros, A. Systemic lupus erythematosus and DNA degradation and elimination defects front. Immunol. 10, 1697–1707 (2019).
Kenny, E. F. et al. mice spontaneously develop a systemic lupus erythematosus-like disease. Eur. J. Immunol. 49, 590–599 (2019).
pubmed: 30758851 doi: 10.1002/eji.201847875
Mamula, M. J. et al. Isoaspartyl post-translational modification triggers autoimmune responses to self-proteins. J. Biol. Chem. 274, 22321–22227 (1999).
pubmed: 10428801 doi: 10.1074/jbc.274.32.22321
Odqvist, L. et al. Genetic variations in A20 DUB domain provide a genetic link to citrullination and neutrophil extracellular traps in systemic lupus erythematosus. Ann. Rheum. Dis. 78, 1363–1370 (2019).
pubmed: 31300459 pmcid: 6788882 doi: 10.1136/annrheumdis-2019-215434
Massarenti, N. et al. Peptidylarginine deiminase-4 Gene Polymorphisms Are Associated With Systemic Lupus Erythematosus and Lupus Nephritis. Scand. J. Rheumatol. 48, 133–140 (2019).
pubmed: 30269634 doi: 10.1080/03009742.2018.1488273
Wang, Y. Novel biomarkers containing citrullinated peptides for diagnosis of systemic lupus erythematosus using protein microarrays. Clin. Exp. Rheumatol. 6, 929–936 (2019).
Louthrenoo, W. et al. The genetic contribution of HLA-DRB5*01:01 to systemic lupus erythematosus in Thailand. Int. J. Immunogenet. 40, 126–130 (2013).
pubmed: 22862923 doi: 10.1111/j.1744-313X.2012.01145.x
Niu, Z., Zhang, P. & Tong, T. Value of HLA-DR genotype in systemic lupus erythematosus and lupus nephritis: a meta-analysis. Int. J. Rheum. Dis. 18, 17–28 (2015).
doi: 10.1111/1756-185X.12528
Ishida-Yamamoto, A. et al. Decreased deiminated Keratin K1 in psoriatic hyperproliferative epidermis. J. Invest. Dermatol. 114, 701–705 (2000).
pubmed: 10733676 doi: 10.1046/j.1523-1747.2000.00936.x
Barrera-Vargas, A. et al. Differential ubiquitination in NETs regulates macrophage responses in systemic lupus erythematosus. Ann. Rheum. Dis. 77, 944–950 (2018).
pubmed: 29588275 pmcid: 6560641
Gladman, D. D., Ibañez, D. & Urowitz, M. B. Systemic lupus erythematosus disease activity index 2000. J. Rheumatol. 29, 288–291 (2002).
pubmed: 11838846
Albrecht, J. & Werth, V. P. Clinical outcome measures for cutaneous lupus erythematosus. Lupus. 19, 1137–1143 (2010).
pubmed: 20693208 pmcid: 3081505 doi: 10.1177/0961203310370049
Aletaha, D. et al. Rheumatoid arthritis classification criteria: an American College of Rheumatology/European League Against Rheumatism collaborative initiative. Arthritis Rheum. 62, 2569–2581 (2010).
pubmed: 20872595 doi: 10.1002/art.27584
Rutgeerts, P. et al. Infliximab for induction and maintenance therapy for ulcerative colitis. N. Engl. J. Med. 353, 2462–2476 (2005).
pubmed: 16339095 doi: 10.1056/NEJMoa050516
LeRoy, E. C. et al. Scleroderma (systemic sclerosis): classification, subsets and pathogenesis. J. Rheumatol. 15, 202–205 (1988).
pubmed: 3361530
Brentville, V. A. et al. Citrullinated vimentin presented on MHC-II in tumor cells is a target for CD4+ T-cell-mediated antitumor immunity. Cancer Res. 76, 548–560 (2016).
pubmed: 26719533 doi: 10.1158/0008-5472.CAN-15-1085
van Heemst, J. et al. Crossreactivity to vinculin and microbes provides a molecular basis for HLA-based protection against rheumatoid arthritis. Nat. Commun. 6, 6681–6691 (2015).
pubmed: 25942574 doi: 10.1038/ncomms7681
Blanc, C., Zufferey, M. & Cosson, P. Use of in vivo biotinylated GST fusion proteins to select recombinant antibodies. ALTEX. 31, 37–42 (2014).
pubmed: 24100547 doi: 10.14573/altex.1307081
Justesen, S., Harndahl, M., Lamberth, K., Nielsen, L. L. & Buus, S. Functional recombinant MHC class II molecules and high-throughput peptide-binding assays. Immunome Res. 5, 2–21 (2009).
pubmed: 19416502 pmcid: 2690590 doi: 10.1186/1745-7580-5-2
Ettinger, R. A. & Kwok, W. W. A peptide binding motif for HLA-DQA1*0102/DQB1*0602, the class II MHC molecule associated with dominant protection in insulin-dependent diabetes mellitus. J. Immunol. 160, 2365–2373 (1998).
pubmed: 9498778
Scholz, E. M. et al. Human leukocyte antigen (HLA)-DRB1*15:01 and HLA-DRB5*01:01 present complementary peptide repertoires. Front. Immunol. 8, 984–995 (2017).
pubmed: 28871256 pmcid: 5566978 doi: 10.3389/fimmu.2017.00984

Auteurs

R Lande (R)

Istituto Superiore di Sanità, National Centre for pre-clinical and clinical drug research and evaluation, Pharmacological research and experimental therapy Unit, 00166, Rome, Italy.
University Hospital CHUV, Dept. of Dermatology, 1011, Lausanne, Switzerland.

R Palazzo (R)

Istituto Superiore di Sanità, National Centre for pre-clinical and clinical drug research and evaluation, Pharmacological research and experimental therapy Unit, 00166, Rome, Italy.

N Gestermann (N)

University Hospital CHUV, Dept. of Dermatology, 1011, Lausanne, Switzerland.

C Jandus (C)

Translational tumor immunology group, Department of fundamental oncology, University of Lausanne, 1066, Epalinges, Switzerland.

M Falchi (M)

Istituto Superiore di Sanità, National AIDS Center, 00166, Rome, Italy.

F Spadaro (F)

Istituto Superiore di Sanità, Confocal Microscopy Unit, Core Facilities, Rome, Italy.

V Riccieri (V)

Division of Rheumatology, Internal medicine and medical specialties, University Sapienza, Rome, Italy.

E A James (EA)

Department of Translational Research, Benaroya Research Institute, Seattle, WA, USA.

A Butera (A)

Istituto Superiore di Sanità, National Centre for pre-clinical and clinical drug research and evaluation, Pharmacological research and experimental therapy Unit, 00166, Rome, Italy.

M Boirivant (M)

Istituto Superiore di Sanità, National Centre for pre-clinical and clinical drug research and evaluation, Pharmacological research and experimental therapy Unit, 00166, Rome, Italy.

L Feldmeyer (L)

University Hospital CHUV, Dept. of Dermatology, 1011, Lausanne, Switzerland.

I Surbeck (I)

University Hospital CHUV, Dept. of Dermatology, 1011, Lausanne, Switzerland.

J Di Lucca (J)

University Hospital CHUV, Dept. of Dermatology, 1011, Lausanne, Switzerland.

F Stuber (F)

University Hospital CHUV, Dept. of Dermatology, 1011, Lausanne, Switzerland.

F R Spinelli (FR)

Division of Rheumatology, Internal medicine and medical specialties, University Sapienza, Rome, Italy.

E Botti (E)

Department of Systems Medicine University of Tor Vergata, Dermatology Unit, Rome, Italy.

B Marinari (B)

Department of Systems Medicine University of Tor Vergata, Dermatology Unit, Rome, Italy.

L Bianchi (L)

Department of Systems Medicine University of Tor Vergata, Dermatology Unit, Rome, Italy.

R Pica (R)

"Sandro Pertini" Hospital, IBD, GE Unit, Rome, Italy.

B Cerbelli (B)

Department of Radiological, oncological and anatomo-pathological sciences, Sapienza University, Rome, Italy.
Department of Medico-Surgical Sciences and Biotechnologies, Sapienza University, Latina, Italy.

K Giannakakis (K)

Department of Pathology, Sapienza University, Rome, Italy.

S E Auteri (SE)

Istituto Superiore di Sanità, National Centre for pre-clinical and clinical drug research and evaluation, Pharmacological research and experimental therapy Unit, 00166, Rome, Italy.
Division of Rheumatology, Internal medicine and medical specialties, University Sapienza, Rome, Italy.

I Daniels (I)

Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UK.

L G Durrant (LG)

Academic Department of Clinical Oncology, University of Nottingham, Nottingham, UK.

S Horstman (S)

Department of Translational Research, Benaroya Research Institute, Seattle, WA, USA.

A Costanzo (A)

Skin pathology laboratory, Dermatology Unit, IRCCS Humanitas clinical and research center, Rozzano, Milan, Italy.

P Romero (P)

Translational tumor immunology group, Department of fundamental oncology, University of Lausanne, 1066, Epalinges, Switzerland.

C Alessandri (C)

Division of Rheumatology, Internal medicine and medical specialties, University Sapienza, Rome, Italy.

F Conti (F)

Division of Rheumatology, Internal medicine and medical specialties, University Sapienza, Rome, Italy.

G Valesini (G)

Division of Rheumatology, Internal medicine and medical specialties, University Sapienza, Rome, Italy.

M Gilliet (M)

University Hospital CHUV, Dept. of Dermatology, 1011, Lausanne, Switzerland.

C Chizzolini (C)

Department of Immunology and Allergy, University Hospital and Medical School, Geneva, Switzerland.

L Frasca (L)

Istituto Superiore di Sanità, National Centre for pre-clinical and clinical drug research and evaluation, Pharmacological research and experimental therapy Unit, 00166, Rome, Italy. loredana.frasca@iss.it.
University Hospital CHUV, Dept. of Dermatology, 1011, Lausanne, Switzerland. loredana.frasca@iss.it.
Department of Immunology and Allergy, University Hospital and Medical School, Geneva, Switzerland. loredana.frasca@iss.it.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Autoanticorps › Anticorps anti-protéines citrullinées › Native/citrullinated LL37-specific T-cells...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Autoanticorps › Anticorps antinucléaires › Native/citrullinated LL37-specific T-cells...
questionsmedicales.fr › Phénomènes du système immunitaire › Immunité › Immunité acquise › Immunité active › Production d'anticorps › Native/citrullinated LL37-specific T-cells...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Perforines › Peptides antimicrobiens cationiques › Native/citrullinated LL37-specific T-cells...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Autoanticorps › Native/citrullinated LL37-specific T-cells...
questionsmedicales.fr › Acides nucléiques, nucléotides et nucléosides › Acides nucléiques › ADN › Native/citrullinated LL37-specific T-cells...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Système phagocytaire mononucléé › Cellules dendritiques › Native/citrullinated LL37-specific T-cells...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Native/citrullinated LL37-specific T-cells...
questionsmedicales.fr › Maladies du système immunitaire › Maladies auto-immunes › Lupus érythémateux disséminé › Native/citrullinated LL37-specific T-cells...
questionsmedicales.fr › Maladies de la peau et du tissu conjonctif › Maladies de la peau › Dermatoses papulosquameuses › Psoriasis › Native/citrullinated LL37-specific T-cells...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Native/citrullinated LL37-specific T-cells...
questionsmedicales.fr › Systèmes sanguin et immunitaire › Système immunitaire › Leucocytes › Agranulocytes › Lymphocytes › Lymphocytes T › Sous-populations de lymphocytes T › Lymphocytes T auxiliaires › Cellules Th17 › Native/citrullinated LL37-specific T-cells...
questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Protéines membranaires › Perforines › Peptides antimicrobiens cationiques › Cathélicidines › Native/citrullinated LL37-specific T-cells...